Xenolith Medical is developing the new generation of “stone filters” that allow effective blockage of stone debris migration during ureteroscopic kidney and bladder procedures, complete removal of trapped debris and considerable simplification of the overall procedure. Kidney stones are a common condition affecting 5-7% of females and 10-12% of males. Around 5 million new cases of kidney and bladder stones are identified worldwide each year. In November 2011, Xenolith Medical has obtained EU CE Mark, which will enable it to market its product in Europe. Xemolith Medical was founded with Xenia in 2010.